NeuroSense Therapeutics Ltd.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $10.8M | $11.1M |
| FY2022 | — | $5.8M | $3.5M |
| FY2023 | — | $-1.8M | $2.6M |
| FY2024 | — | $2.6M | $3.4M |
| FY2025 | — | $-1.6M | $166.0K |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $10.8M | $11.1M |
| FY2022 | — | $5.8M | $3.5M |
| FY2023 | — | $-1.8M | $2.6M |
| FY2024 | — | $2.6M | $3.4M |
| FY2025 | — | $-1.6M | $166.0K |